MX2010010457A - Vectores recombinantes de rinovirus. - Google Patents

Vectores recombinantes de rinovirus.

Info

Publication number
MX2010010457A
MX2010010457A MX2010010457A MX2010010457A MX2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A MX 2010010457 A MX2010010457 A MX 2010010457A
Authority
MX
Mexico
Prior art keywords
rhinovirus vectors
vectors
recombinant rhinovirus
recombinant
immunogens
Prior art date
Application number
MX2010010457A
Other languages
English (en)
Inventor
Kirill Kalnin
Yanhua Yan
Maryann Giel-Moloney
Harold Kleant-Hous
Original Assignee
Sanofi Pasteur Biologics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co filed Critical Sanofi Pasteur Biologics Co
Publication of MX2010010457A publication Critical patent/MX2010010457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32741—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La invención proporciona vectores de rinovirus, los cuales pueden usarse en la entrega de inmunógenos, tales como inmunógenos de virus de la influenza, y composiciones y métodos correspondientes.
MX2010010457A 2008-03-27 2009-03-27 Vectores recombinantes de rinovirus. MX2010010457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7203608P 2008-03-27 2008-03-27
PCT/US2009/001941 WO2009120380A2 (en) 2008-03-27 2009-03-27 Recombinant rhinovirus vectors

Publications (1)

Publication Number Publication Date
MX2010010457A true MX2010010457A (es) 2010-11-05

Family

ID=41114548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010457A MX2010010457A (es) 2008-03-27 2009-03-27 Vectores recombinantes de rinovirus.

Country Status (11)

Country Link
US (1) US20110091501A1 (es)
EP (1) EP2257308A4 (es)
JP (1) JP2011517408A (es)
KR (1) KR20110005826A (es)
CN (1) CN102089003A (es)
AU (1) AU2009229165A1 (es)
BR (1) BRPI0909119A2 (es)
CA (1) CA2718731A1 (es)
IL (1) IL208321A0 (es)
MX (1) MX2010010457A (es)
WO (1) WO2009120380A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007347184A1 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
CN105399833B (zh) 2010-01-04 2019-09-06 Kj 生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
US9566307B2 (en) * 2012-04-19 2017-02-14 Kyushu University, National University Corporation Pharmaceutical composition
EP3193922B1 (en) * 2014-09-18 2019-08-28 GlaxoSmithKline Biologicals S.A. Vaccine
EP3095866B1 (de) 2015-05-20 2019-05-08 Secarna Pharmaceuticals GmbH & Co. KG Mittel zur prophylaxe und therapie von virusinfektionen
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
WO2016205389A1 (en) * 2015-06-15 2016-12-22 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
US10428116B2 (en) * 2016-04-22 2019-10-01 Wisconsin Alumni Research Foundation Rhinovirus C immunogenic peptides
CN109694401A (zh) * 2017-10-20 2019-04-30 金协国际实业有限公司 败血性巴氏杆菌毒素重组蛋白、其类病毒颗粒及其应用
CN115991744A (zh) * 2021-07-26 2023-04-21 北京万泰生物药业股份有限公司 人鼻病毒的通用亲和表位多肽、抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
EP1256803A1 (en) * 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
CN1551782A (zh) * 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
US20060088549A1 (en) * 2004-07-08 2006-04-27 Arnold Gail F Chimeric virus vaccine
WO2007082734A2 (en) * 2006-01-17 2007-07-26 Creatogen Laboratories Gmbh Influenza vaccine
EP1991264B1 (en) * 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
AU2007347184A1 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
EP2066343B1 (en) * 2006-09-29 2017-06-14 Sanofi Pasteur Biologics, LLC Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
CA2676689C (en) * 2007-01-31 2014-12-16 Sanofi Pasteur Biologics Co. Recombinant bicistronic flavivirus vectors
US20110110973A1 (en) * 2008-02-09 2011-05-12 Sanofi Pasteur Biologics Co. Influenza B Vaccines
BRPI0908936A2 (pt) * 2008-03-14 2017-03-28 Sanofi Pasteur Biologics Co vacinas de flavivírus de replicação defeituosa e vetores de vacina

Also Published As

Publication number Publication date
CA2718731A1 (en) 2009-10-01
KR20110005826A (ko) 2011-01-19
EP2257308A2 (en) 2010-12-08
AU2009229165A1 (en) 2009-10-01
EP2257308A4 (en) 2012-06-27
JP2011517408A (ja) 2011-06-09
IL208321A0 (en) 2010-12-30
US20110091501A1 (en) 2011-04-21
WO2009120380A2 (en) 2009-10-01
WO2009120380A3 (en) 2009-12-30
BRPI0909119A2 (pt) 2017-06-13
CN102089003A (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
MX2010010457A (es) Vectores recombinantes de rinovirus.
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EA201100268A1 (ru) Вакцина
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX2010004374A (es) Armazones proteinicos.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
GB0917002D0 (en) Improved shigella blebs
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
JO2860B1 (en) Phenylendazolyl compounds
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
MY161495A (en) Virus like particle compositions and methods of use
SG195194A1 (en) Nanogels
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
MX2010005589A (es) Composicion para el cuidado personal.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
MX2011008179A (es) Peptidos para vacuna.
WO2011098778A3 (en) Peptides for vaccines against birch allergy
WO2009152167A3 (en) Delivery of therapeutics
MX2009003300A (es) Vectores de rhinovirus recombinantes.
MY165088A (en) Pharmaceutical compositions comprising alisporivir

Legal Events

Date Code Title Description
FA Abandonment or withdrawal